Israeli imaging analysis software developer CathWorks has raised $30 million in a series C round of investment funding. CathWorks said the round was led by Deerfield Management.
CathWorks has developed the FFRangio fractional flow reserve (FFR) analysis software, which was cleared by the U.S. Food and Drug Administration in December 2018.
FFRangio is designed to deliver FFR guidance for optimizing percutaneous coronary intervention (PCI) procedures, without the invasiveness of a conventional FFR procedure. It uses data derived from images acquired during a coronary angiography exam, providing a 3D reconstruction of the entire coronary tree with FFR values along each vessel.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
